Why finding a blood test for Alzheimer’s could be the key to new treatments

| | December 11, 2019
t larg alzheimers
Image: CNN
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Alzheimer’s patients who were at earlier stages of the disease did better than those with more advanced cognitive decline [in clinical trials], says Colin Masters, a neuroscientist at Florey Institute of Neuroscience and Mental Health in Australia who was not involved in the trials. This indicates that the key to finding an effective treatment might be to catch subjects before their condition advances too far.

Thanks to the recent development of new detection technologies that yield more-precise and reliable measurements of circulating proteins, RNAs, and other molecules, the field is hoping to do just that. Using these analytic tools, which weren’t available just a few years ago, multiple labs around the world are now searching for new biomarkers of the disease to develop blood tests that can screen for early signs of Alzheimer’s, differentiate it from conditions with similar symptoms, or track its progression.

Related article:  Does gum disease causes Alzheimer’s? We are a long way from an answer, researcher says

According to Henrik Zetterberg, a biomarkers researcher at the University of Gothenburg in Sweden, improvements in the analysis of protein composition in blood samples have driven an explosion of research—and promising results—over the past decade.

Read full, original post: The Hunt for a Blood Test for Alzheimer’s Disease

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend